Comparative Pharmacology
Head-to-head clinical analysis: MYTREX A versus SULFAMETHOPRIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYTREX A versus SULFAMETHOPRIM.
MYTREX A vs SULFAMETHOPRIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methotrexate inhibits dihydrofolate reductase, leading to depletion of tetrahydrofolate and inhibition of DNA synthesis and cell proliferation. Also has immunomodulatory effects via adenosine release.
Sulfamethoprim is a combination of sulfamethoxazole and trimethoprim. Sulfamethoxazole inhibits bacterial dihydropteroate synthase, blocking folic acid synthesis; trimethoprim inhibits bacterial dihydrofolate reductase, also blocking folic acid synthesis. This sequential blockade produces bactericidal effects.
Methotrexate (MYTREX A) 7.5-25 mg orally once weekly, or 15-25 mg intramuscularly/subcutaneously once weekly for rheumatoid arthritis; in oncology, dosing varies per protocol.
Oral or intravenous: 800 mg sulfamethoxazole / 160 mg trimethoprim every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours in normal renal function; prolonged to 24-30 hours in moderate to severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 8-12 hours in adults with normal renal function. Prolonged in renal impairment (up to 24-48 hours).
Renal: 90% unchanged drug; fecal: <10% via bile; minor hepatic metabolism to inactive metabolites.
Renal: 60-80% as unchanged drug via glomerular filtration and tubular secretion; biliary: 5-10%; fecal: <5%.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic